SG11201700073PA - Methods for the treatment of hepatitis b and hepatitis d virus infections - Google Patents

Methods for the treatment of hepatitis b and hepatitis d virus infections

Info

Publication number
SG11201700073PA
SG11201700073PA SG11201700073PA SG11201700073PA SG11201700073PA SG 11201700073P A SG11201700073P A SG 11201700073PA SG 11201700073P A SG11201700073P A SG 11201700073PA SG 11201700073P A SG11201700073P A SG 11201700073PA SG 11201700073P A SG11201700073P A SG 11201700073PA
Authority
SG
Singapore
Prior art keywords
hepatitis
treatment
methods
virus infections
infections
Prior art date
Application number
SG11201700073PA
Other languages
English (en)
Inventor
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55063440&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201700073P(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of SG11201700073PA publication Critical patent/SG11201700073PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
SG11201700073PA 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections SG11201700073PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462022846P 2014-07-10 2014-07-10
US201462091943P 2014-12-15 2014-12-15
PCT/CA2015/050626 WO2016004525A1 (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Publications (1)

Publication Number Publication Date
SG11201700073PA true SG11201700073PA (en) 2017-02-27

Family

ID=55063440

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700073PA SG11201700073PA (en) 2014-07-10 2015-07-07 Methods for the treatment of hepatitis b and hepatitis d virus infections

Country Status (32)

Country Link
US (1) US9603865B2 (pl)
EP (1) EP3166615B1 (pl)
JP (2) JP2017521433A (pl)
KR (2) KR20170029577A (pl)
CN (2) CN106659730A (pl)
AU (1) AU2015286199B2 (pl)
BR (1) BR112017000320B1 (pl)
CA (1) CA2954182C (pl)
CL (1) CL2017000008A1 (pl)
CU (1) CU20170001A7 (pl)
DK (1) DK3166615T3 (pl)
DO (1) DOP2017000002A (pl)
EA (1) EA036745B1 (pl)
EC (1) ECSP16097355A (pl)
ES (1) ES2963814T3 (pl)
FI (1) FI3166615T3 (pl)
HK (1) HK1231402A1 (pl)
HR (1) HRP20231400T1 (pl)
HU (1) HUE064449T2 (pl)
IL (1) IL249660B (pl)
LT (1) LT3166615T (pl)
MD (1) MD4760C8 (pl)
MX (1) MX2017000053A (pl)
MY (1) MY178087A (pl)
PH (1) PH12017500010A1 (pl)
PL (1) PL3166615T3 (pl)
PT (1) PT3166615T (pl)
RS (1) RS64833B1 (pl)
SG (1) SG11201700073PA (pl)
SI (1) SI3166615T1 (pl)
TW (1) TWI766831B (pl)
WO (1) WO2016004525A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53674A (fr) * 2018-11-08 2021-07-28 Aligos Therapeutics Inc Polymères oligonucléotidiques inhibant le transport de l'antigène s et procédés
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021223398A1 (zh) * 2020-05-07 2021-11-11 西安新通药物研究股份有限公司 治疗肝病的晶型及其应用
CN113620993A (zh) * 2020-05-07 2021-11-09 西安新通药物研究股份有限公司 甲磺酸帕拉德福韦d晶型及其应用
CN114057816A (zh) * 2020-07-30 2022-02-18 浙江柏拉阿图医药科技有限公司 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用
CA3200094A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
WO2022133230A1 (en) 2020-12-18 2022-06-23 Janssen Pharmaceuticals, Inc. Combination therapy for treating hepatitis b virus infection
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
WO2022261046A1 (en) * 2021-06-07 2022-12-15 Antios Therapeutics, Inc. Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs
WO2023281434A1 (en) 2021-07-09 2023-01-12 Janssen Pharmaceuticals, Inc. Use of oligonucleotides for individuals with renal impairment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482836A (en) * 1993-01-14 1996-01-09 The Regents Of The University Of California DNA purification by triplex-affinity capture and affinity capture electrophoresis
AU2003267785C1 (en) 2002-09-13 2009-12-24 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
WO2006091798A2 (en) * 2005-02-22 2006-08-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus
JP5775581B2 (ja) 2010-08-20 2015-09-09 レプリコール インコーポレーティッド オリゴヌクレオチドキレート錯体
EP3766975A1 (en) * 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
WO2012075114A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Nucleic acid-polymer conjugates and uses thereof
CN104349793B (zh) * 2012-05-18 2017-11-10 里普利科股份有限公司 寡核苷酸螯合物‑多肽组合物和方法
JP6270846B2 (ja) 2012-08-30 2018-01-31 レプリコール インコーポレーティッド Ｂ型肝炎感染及びｄ型肝炎感染の治療方法

Also Published As

Publication number Publication date
TW201613617A (en) 2016-04-16
JP2017521433A (ja) 2017-08-03
EA201790160A1 (ru) 2017-06-30
EP3166615A4 (en) 2018-01-17
CN106659730A (zh) 2017-05-10
DK3166615T3 (da) 2023-11-13
SI3166615T1 (sl) 2023-12-29
KR20170029577A (ko) 2017-03-15
CA2954182A1 (en) 2016-01-14
MD4760B1 (ro) 2021-07-31
HK1231402A1 (zh) 2017-12-22
FI3166615T3 (fi) 2023-11-06
EP3166615B1 (en) 2023-08-09
IL249660A0 (en) 2017-02-28
MX2017000053A (es) 2017-05-01
BR112017000320A2 (pt) 2017-11-07
BR112017000320B1 (pt) 2023-02-07
CL2017000008A1 (es) 2017-06-09
HRP20231400T1 (hr) 2024-02-16
MD20170014A2 (ro) 2017-07-31
PL3166615T3 (pl) 2024-02-19
CN113750112A (zh) 2021-12-07
WO2016004525A1 (en) 2016-01-14
RS64833B1 (sr) 2023-12-29
ECSP16097355A (es) 2017-03-31
JP6922030B2 (ja) 2021-08-18
MY178087A (en) 2020-10-02
TWI766831B (zh) 2022-06-11
AU2015286199A1 (en) 2017-02-23
MD4760C8 (ro) 2022-02-28
AU2015286199B2 (en) 2020-05-14
DOP2017000002A (es) 2017-03-15
PT3166615T (pt) 2023-11-13
ES2963814T3 (es) 2024-04-02
EP3166615A1 (en) 2017-05-17
US9603865B2 (en) 2017-03-28
PH12017500010A1 (en) 2017-05-15
EA036745B1 (ru) 2020-12-16
CU20170001A7 (es) 2017-04-05
IL249660B (en) 2022-02-01
KR20230070330A (ko) 2023-05-22
HUE064449T2 (hu) 2024-03-28
US20160008393A1 (en) 2016-01-14
LT3166615T (lt) 2024-01-25
JP2020143065A (ja) 2020-09-10
CA2954182C (en) 2023-08-15

Similar Documents

Publication Publication Date Title
IL280459A (en) Phosphoramidates for the treatment of hepatitis B virus
HRP20190352T1 (hr) Novi 6-kondenzirani heteroarildihidropirimidini za liječenje i profilaksu infekcije virusom hepatitisa b
HK1223931A1 (zh) 用於治療和預防乙型肝炎病毒感染的新型二氫喹嗪酮類化合物
IL263972A (en) Dihydropyranopyrimidines for the treatment of viral infections
EP3240787A4 (en) Derivatives and methods of treating hepatitis b infections
IL246678A0 (en) History of Azpan and methods of treating jaundice b infections
EP3139954A4 (en) Methods and compositions for treating hepatitis b virus infections
HK1225389A1 (zh) 氨磺酰基吡咯酰胺衍生物及其作為藥物用於治療乙型肝炎的用途
HK1231402A1 (zh) 治療 型肝炎和 型肝炎病毒感染的方法
IL273932A (en) Methods of treatment and prevention of viral infection
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
HK1249046A1 (zh) 治療b型肝炎病毒的方法
PL3137078T3 (pl) Leczenie zakażenia wirusem zapalenia wątroby typu delta
EP3226973A4 (en) Treatment of hepatitis delta virus infection
ZA201604784B (en) Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
TH1601001266A (th) วิธีการและองค์ประกอบทางเภสัชกรรมสำหรับการบำบัดการติดเชื้อไวรัสตับอักเสบ b
AU2014900488A0 (en) Agents and methods for inhibiting virus infection